Acurx Actively Enrolling Patients in Ph2 Clinical Trial of its Lead Antibiotic for Treatment of Clostridioides difficile Infection (CDI) Jul 23, 2020
Acurx Receives USAN Approval of Non-proprietary Name Ibezapolstat for Its Phase 2 Novel, First-in-Class Antibiotic for C. difficile Infection Jan 15, 2020
Acurx's Novel Lead Antibiotic Candidate Presented at Two Prominent International Scientific Conferences Oct 3, 2019
Acurx Receives FDA Fast Track Designation for ACX-362E for the Treatment of C. difficile infection Jan 16, 2019
Acurx Pharmaceuticals to Enter Clinical Trials with First-In-Class Antibiotics to Treat Selected Gram-Positive Bacterial Infections Oct 4, 2018
FDA Grants QIDP Designation to Acurx’s Lead Antibiotic Product Candidate, ACX-362E for Clostridium Difficile Infection Jun 20, 2018
